QP 01 - GU 4: GU Quick Pitch

Moderator(s)

• 

  Sagar Patel, MD

  Emory University
  Atlanta, GA, United States
• 

  Sophia Kamran, MD

  Massachusetts General Hospital
  Boston, MA, United States

Presentations:

• 8:00 AM – 8:05 AM ET

  Introduction
• 8:05 AM – 8:10 AM ET

  Impact of Prior Local Therapy (LT) on Treatment Response and Survival of Men with Metastatic Castrate Resistant Prostate Cancer (mCRPC): A Pooled Analysis of COU-AA-302 and ACIS Trials
  

  Presenter: Omar Azem, MD – Rush University Medical Center
• 8:10 AM – 8:15 AM ET

  Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients with Localized Prostate Cancer: Toxicity and Quality-of Life Results from a Prospective Trial
  

  Presenter: Chia-Lin Tseng, MD – Sunnybrook Health Sciences Centre
• 8:15 AM – 8:20 AM ET

  Radiotherapy of the Primary Tumor and All Metastatic Lesions in Oligometastatic Prostate Cancer: 5-Year Results of Prolong Study
  

  Presenter: Xin Qi, MD, MS – Peking University First Hospital
• 8:20 AM – 8:25 AM ET

  Initial Results of a Phase 2 Trial of Stereotactic Body Radiation Therapy, Hormone/Androgen Deprivation Therapy and Radium 223 Dichloride for Oligometastatic Castrate Sensitive Prostate Cancer (SHARP)
  

  Presenter: Savita Dandapani, MD, PhD – City of Hope Comprehensive Cancer Center
• 8:25 AM – 8:30 AM ET

  Stereotactic Body Radiation Therapy (SBRT) Combined with Pelvic Radiotherapy and GTV Boost Based on Multiparameter Magnetic Resonance Image for High-Risk Prostate Cancer: A Phase II Study
  

  Presenter: Ouying Yan
• 8:30 AM – 8:35 AM ET

  A Prospective Pilot Study Investigating ¹⁸F rhPSMA-7.3 PET/MRI to Detect Recurrent Disease and Guide Radiotherapy Planning in Patients with Biochemically Recurrent Prostate Cancer Post-Pros
  

  Presenter: Devaki Shilpa Surasi, MD – MD Anderson Cancer Center
• 8:35 AM – 8:55 AM ET

  Questions and Answers
• 8:55 AM – 9:00 AM ET

  Closing